{"product_id":"generic-eribulin-mesylate-injection","title":"Eribulin mesylate Injection","description":"\u003ch2\u003eAbout Eribulin mesylate Injection\u003c\/h2\u003e\u003cp\u003eEribulin is a chemotherapy drug.  It's a treatment for breast cancer and liposarcoma that has: spread to surrounding tissue (locally advanced cancer) spread to other areas of the body (metastatic or advanced cancer)\u003c\/p\u003e\u003cul\u003e\u003cli\u003eGeneric (Eribulin mesylate) sold as brand name 博立宁® in china.\u003c\/li\u003e\u003c\/ul\u003e\u003ch3\u003eBreast Cancer, Metastatic\u003c\/h3\u003e\u003cp\u003eIndicated for metastatic breast cancer in patients who have previously received at least 2 chemotherapeutic regimens for the treatment of metastatic disease; prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting\u003c\/p\u003e\u003cp\u003e1.4 mg\/m² IV infused over 2-5 min on days 1 and 8 of 21-day cycle \u003ca class=\"calc_link\" data-calc=\"bsa-dosing\" data-cond=\"\" data-sec=\"Adult Dosing \u0026amp; Uses\" data-text=\"1.4 mg\/m² IV infused over 2-5 min on days 1 and 8 of 21-day cycle\"\u003e \u003c\/a\u003e\u003c\/p\u003e\u003ch3\u003eLiposarcoma\u003c\/h3\u003e\u003cp\u003eIndicated for unresectable or metastatic liposarcoma in patients who have received a prior anthracycline-containing regimen\u003c\/p\u003e\u003cp\u003e1.4 mg\/m² IV infused over 2-5 min on days 1 and 8 of 21-day cycle \u003ca class=\"calc_link\" data-calc=\"bsa-dosing\" data-cond=\"\" data-sec=\"Adult Dosing \u0026amp; Uses\" data-text=\"1.4 mg\/m² IV infused over 2-5 min on days 1 and 8 of 21-day cycle\"\u003e \u003c\/a\u003e\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003eAssess for peripheral neuropathy and obtain CBC counts prior to each dose\u003c\/p\u003e\u003ch4\u003eRecommended dose delays\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eDo not administer on Day 1 or Day 8 for any of the following\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eANC \u0026lt;1,000\/mm³\u003c\/li\u003e\n\u003cli\u003ePlatelets \u0026lt;75,000\/mm³\u003c\/li\u003e\n\u003cli\u003eGrade 3 or 4 nonhematological toxicities\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eThe Day 8 dose may be delayed for a maximum of 1 week:\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eIf toxicities do not resolve or improve to ≤Grade 2 severity by Day 15, omit the dose\u003c\/li\u003e\n\u003cli\u003eIf toxicities resolve or improved to ≤Grade 2 severity by Day 15, administer at a reduced dose and initiate the next cycle no sooner than 2 weeks later\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRecommended dose reductions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eIf a dose has been delayed for toxicity and then recovered to ≤Grade 2 severity, resume at reduced doses (see below)\u003c\/li\u003e\n\u003cli\u003eDo not re-escalate once dose has been reduced\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003ePermanently reduce the 1.4 mg\/m² dose to 1.1 mg\/m² for any of the following:\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eANC \u0026lt;500\/mm³ for \u0026gt;7 days\u003c\/li\u003e\n\u003cli\u003eANC \u0026lt;1,000\/mm³ with fever or infection\u003c\/li\u003e\n\u003cli\u003ePlatelets \u0026lt;25,000\/mm³\u003c\/li\u003e\n\u003cli\u003ePlatelets \u0026lt;50,000\/mm³ requiring transfusion\u003c\/li\u003e\n\u003cli\u003eNonhematologic Grade 3 or 4 toxicities\u003c\/li\u003e\n\u003cli\u003eOmission or delay of Day 8 dose in previous cycle for toxicity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003ePermanently reduce dose to 0.7 mg\/m² for any of the following:\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eOccurrence of any event requiring permanent dose reduction while receiving 1.1 mg\/m²\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eDiscontinue\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eOccurrence of any event requiring permanent dose reduction while receiving 0.7 mg\/m²\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eModerate-to-severe (CrCl 15-49 mL\/min): 1.1 mg\/m² IV\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild (Child-Pugh A): 1.1 mg\/m² IV\u003c\/li\u003e\n\u003cli\u003eModerate (Child-Pugh B): 0.7 mg\/m² IV\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"BrightGene Bio-Medical Technology Co Ltd","offers":[{"title":"Default Title","offer_id":44797955833899,"sku":"RL3120241211s130","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2024-12-1111.png?v=1787022242","url":"https:\/\/xomeds.com\/products\/generic-eribulin-mesylate-injection","provider":"XOMEDS","version":"1.0","type":"link"}